ZB
$28.23
+0.15
(+0.53%)
As of Oct 22, 2026, 9:33 PM EDT
Price history
Zenas Biopharma Inc (ZBIO) is trading up at $28.23 (+0.53%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
IPO: September 13, 2024 · $17.00 offering · NASDAQ · View IPO details →
Zenas Biopharma Inc revenue & net income history (FY2023–FY2025)
RevenueNet incomeNet margin (right axis, %)
| FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|
| Income statement | |||
| Revenue | $50.0M | $5.00M | $10.0M |
| Growth (year over year) | — | −90.0% | +100.0% |
| Operating income | −$37.1M | −$163.9M | −$383.1M |
| Operating margin | −74.3% | −3277.8% | −3830.6% |
| Net income | −$37.1M | −$157.0M | −$377.7M |
| Net margin | −74.2% | −3139.8% | −3777.4% |
| EPS (diluted) | −$24.25 | −$11.89 | −$8.44 |
| Balance sheet | |||
| Cash and equivalents | $56.9M | $319.7M | $110.6M |
| Total assets | $68.2M | $370.0M | $383.6M |
| Total liabilities | $43.8M | $57.5M | $141.5M |
| Long-term debt | — | — | $78.6M |
| Shareholders' equity | −$225.7M | $312.5M | $242.1M |
| Cash flow | |||
| Operating cash flow | −$30.5M | −$119.7M | −$172.3M |
| Capital expenditure | $17.0K | $131.0K | $18.0K |
| Free cash flow | −$30.5M | −$119.8M | −$172.4M |
RevenueNet incomeNet margin (right axis, %)
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26†Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | — | $10.0M | $0 | $0 | — | $0 | $1.00M |
| Growth (year over year) | −100.0% | — | — | — | — | — | −100.0% | — |
| Operating income | −$41.0M | — | −$37.3M | −$55.2M | −$52.6M | — | −$77.3M | −$107.7M |
| Operating margin | — | — | −373.3% | — | — | — | — | −10765.9% |
| Net income | −$38.6M | — | −$33.6M | −$52.2M | −$51.5M | — | −$81.0M | −$111.5M |
| Net margin | — | — | −335.7% | — | — | — | — | −11145.6% |
| EPS (diluted) | −$5.02 | — | −$0.80 | −$1.25 | −$1.22 | — | −$1.46 | −$1.77 |
| Balance sheet | ||||||||
| Cash and equivalents | $360.0M | $319.7M | $196.6M | $44.0M | $115.6M | $110.6M | $500.2M | $196.6M |
| Total assets | $403.4M | $370.0M | $333.8M | $293.1M | $322.0M | $383.6M | $747.7M | $701.7M |
| Total liabilities | $44.0M | $57.5M | $49.4M | $53.5M | $125.6M | $141.5M | $411.9M | $454.6M |
| Long-term debt | — | — | — | — | $73.0M | $78.6M | — | — |
| Shareholders' equity | $359.4M | $312.5M | $284.3M | $239.6M | $196.4M | $242.1M | $335.8M | $247.1M |
| Cash flow | ||||||||
| Operating cash flow | −$31.1M | — | −$37.1M | −$41.7M | −$41.1M | — | −$75.2M | −$57.2M |
| Capital expenditure | $0 | — | $18.0K | $0 | $0 | — | $2.00K | $0 |
| Free cash flow | −$31.1M | — | −$37.1M | −$41.7M | −$41.1M | — | −$75.2M | −$57.2M |
From Zenas Biopharma Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Zenas Biopharma Inc
- Headquarters
- Waltham, Massachusetts From SEC filings, Oct 2026
Recent News (2)
-
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WALTHAM, Mass., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in th…
-
Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease – Phase 3 INDIGO open-label extension findings demonstrated sustained clinical activity of obexelimab –
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International